• Acute Lymphoblastic Leukemia Fact Sheet
    PDF
    lock
    Disease Awareness / Fact Sheet
    Acute Lymphoblastic Leukemia Fact Sheet

    Acute lymphoblastic leukemia (ALL) is a cancer of the blood and lymphocytes, and is a common cancer diagnosis in children.

  • Document on Acute Lymphoblastic Leukemia (ALL)
    PDF
    lock
    Disease Awareness / Fact Sheet
    Acute Lymphoblastic Leukemia (ALL)

    Acute lymphoblastic leukemia (ALL) is a cancer of the lymphocytes.Leukemia, a cancer of the blood, begins when normal blood cells change and grow uncontrollably. Acute lymphocytic leukemia is a cancer of the lymphocytes, a type of white blood cell involved in the body’s immune system.

  • Document on Diffuse Large B-cell Lymphoma
    PDF
    lock
    Disease Awareness / Fact Sheet
    Diffuse Large B-Cell Lymphoma (DLBCL)

    While there are many different sub-types of non-Hodgkin lymphoma (NHL), each are unique in how they present in patients and how they should be treated. Diffuse large B-cell lymphoma (DLBCL) is an aggressive (fast-growing), complex and difficult- to-treat form of NHL. NHL refers to a group of cancers of the lymphatic system that develop from the lymphocytes, a type of white blood cell involved in the body’s immune system.

  • About Migraine
    PDF
    lock
    Disease Awareness / Fact Sheet
    About Migraine

    Migraine can have up to four distinct phases—premonitory (or prodrome), aura, headache and post-drome— and each of them has many potential symptoms.

  • Heart failure hospitalization: Why this moment matters
    PDF
    lock
    Disease education / Fact Sheet
    Heart failure hospitalization: why this moment matters

    Hospitalization provides an opportunity for physicians to optimize heart failure treatment to reduce the likelihood of hospital readmission and death, reduce the burden of hospitalizations, and improve outcomes for patients living with heart failure.

  • Spinal Muscular Atrophy (SMA) Infographic
    PDF
    lock
    Disease education / Fact Sheet
    Spinal Muscular Atrophy (SMA) Factsheet

    Novartis and AveXis combine, aiming to transform the care of SMA, the #1 genetic cause of infant mortality.

  • Strengthening our Global Health & Corporate Responsibility function, PDF preview
    PDF
    lock
    Corporate Responsibility / Fact Sheet
    Strengthening our Global Health & Corporate Responsibility function

    The factsheet “Strengthening our Global Health & Corporate Responsibility function” provides an overview of our Global Health & Corporate Responsibility governance, structure, strategic priorities and commitments.

  • Building trust with society: our priorities, PDF preview
    PDF
    lock
    Corporate Responsibility / Fact Sheet
    Building trust with society: our priorities

    The fact sheet “Building trust with society: our priorities” provides key highlights around 4 areas: pricing and access to medicines; global health challenges; ethical standards; and corporate responsibility.

  • Novartis Access one-year report
    PDF
    lock
    Novartis Social Business / Report
    Novartis Access one-year report

    The Novartis Access one-year report describes first results, early learnings and challenges from our first twelve months on the ground. It also includes external perspectives and country updates, showcasing the progress we have made as we roll out the program.

  • Novartis Access 2017 Two-Year Report
    PDF
    lock
    Novartis Access / Report
    Novartis Access two-year report

    Since 2015, Novartis Access has worked to deliver treatments for chronic diseases in lower-income countries. Read our two-year report for an in-depth look at results, learnings and challenges on the ground so far. It includes external perspectives and country updates, showcasing the progress we have made as we roll out the program.

  • Corporate Responsibility Report 2017
    PDF
    lock
    Corporate Responsibility / Report
    Corporate Responsibility Report 2017

    As a leading healthcare company, we have a responsibility to help people get access to the treatments they need, no matter where they live. Our CR Performance Report gives you all the facts on the progress we are making. It is issued at the same time as our Annual Report to provide readers with a more integrated view of Novartis.

  • Healthy Family
    PDF
    lock
    Novartis Social Business / Report
    Healthy Family 10-year report

    10 years ago we launched the Healthy Family program, Novartis first social business model, to improve health via education, affordable products and health services. This report provides information on how the program has evolved since then. It includes external perspectives and country updates, showcasing the learnings and progress we have made over the years.